Publications
- Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry2023 | Third Faculty of Medicine, First Faculty of Medicine
- Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry2022 | Third Faculty of Medicine, First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
- Choice of biological therapy in terms of psoriasis comorbidities2022 | Third Faculty of Medicine
- Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study2022 | Third Faculty of Medicine
- Dermatitis Herpetiformis With Flame Figures-An Unusual Case Description2022 | Third Faculty of Medicine
- Coexistence of palmoplantar pustulosis and ichthyosis vulgaris treated by risankizumab2021 | Third Faculty of Medicine
- Photoprotection in drug-induced photosensitivity2020 | Third Faculty of Medicine
- Tumor necrosis factor alpha (TNFα) inhibitors in the treatment of severe forms of psoriasis2017 | Third Faculty of Medicine
- Severe psoriasis treated with ustekinumab2013 | Third Faculty of Medicine
- Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer2023 | Third Faculty of Medicine
Loading network view...